Objective: Several studies have reported the association of benign paroxysmal positional vertigo (BPPV) with vitamin D deficiency. This study aimed to evaluate serum 25-hydroxy vitamin D (25 (OH) D) levels in native Chinese postmenopausal women with de novo idiopathic BPPV and to investigate the possible relationship between the occurrence of BPPV and low 25 (OH) D levels. Methods: This retrospective study comprised of 85 postmenopausal women with de novo idiopathic BPPV and 80 age-matched healthy controls. All subjects had bone mineral density (BMD) and serum 25 (OH) D levels measurements recorded, and the results were compared. Results: The prevalence of reduced BMD (T score <−1.0) was significantly higher in female patients with BPPV than in healthy controls (71.8% vs. 51.2%, p = .004). The mean serum 25 (OH) D levels were also significantly lower in female patients with BPPV than in healthy controls (19.1 ± 5.2 vs. 22.5 ± 5.8, p < .001). The regression analyses demonstrated that vitamin D deficiency was associated with BPPV with an odds ratio of 2.1 (95% confidence interval = 1.1–3.1, p = .031). Conclusion: Our study suggests that low 25 (OH) D may be a risk factor for BPPV in postmenopausal women.
Objective: Otolin-1, a main specific otoconia matrix protein, passes through the labyrinth-blood barrier and is detectable in peripheral blood. Serum otolin-1 levels differ between patients with benign paroxysmal positional vertigo (BPPV) and healthy controls and are significantly age-related, increasing in healthy controls with age, suggesting that serum otolin-1 levels reflect otolith status. The aim of this study was to determine whether otolin-1 levels change during vertigo episodes in patients with BPPV and whether any change is specific and sensitive enough for BPPV episodes. Method: Patients diagnosed with de novo idiopathic BPPV during an acute episode were included in the study from May 2017 to May 2018. Blood samples were drawn before patients were treated with canalith-repositioning maneuvers. Serum otolin-1 levels were compared between 78 patients and 121 age- and sex-matched healthy individuals. Results: There were no significant differences between the groups in the age distribution, sex ratio, body mass index, clinical history, routine blood parameters, or total protein, albumin, uric acid, creatinine, blood urea nitrogen and lipid profiles (P > 0.05). Serum levels of otolin-1 were significantly higher in BPPV patients than in healthy controls (P < 0.001). Receiver operating characteristic analysis revealed that a serum otolin-1 value of 299.45 pg/ml was the optimal cut-off value to discriminate patients with BPPV from healthy controls (area under the curve 0.757, 95% CI 0.687~0.826) with a sensitivity of 67.9% and a specificity of 72.7%. Conclusion: Serum levels of otolin-1 may be a potential biomarker for BPPV episodes.
Background: Otolin-1 is an inner ear-specific protein that is exclusively expressed in otoconia and vestibule and cochlea cells. Recent investigations reported that otolin-1 can cross the blood-labyrinthine barrier and that the levels in serum well-reflected otolith status. Serum otolin-1 levels in patients with benign paroxysmal positional vertigo (BPPV) are significantly elevated compared with healthy controls. We aimed to explore whether otolin-1 can also serve as a biomarker for predicting BPPV recurrence.Method: Patients at our institution with new-onset of idiopathic BPPV between May, 2017 and May, 2018 were recruited and followed up for 2 years. All demographic data of the patients were collected, and serum levels of otolin-1 and other laboratory indicators were measured and compared according to the recurrence status.Results: A total of 74 patients, who met the inclusion criteria were enrolled in this study, of which 27 (36.5%) patients had suffered one or more episodes of recurrence after undergoing canal repositioning treatments during the study. The serum levels of otolin-1 in patients with recurrent BPPV were significantly higher than those in patients without recurrent BPPV (363.9 vs. 309.8 pg/ml, p = 0.001). In multivariate analysis comparing the second to fourth quartiles (Q2–Q4) against the first quartile (Q1) of otolin-1, the level of otolin-1 in Q4 could significantly predict BPPV recurrence, and the odds ratio (OR) was elevated by approximately 812% (OR = 9.12; 95% confidence interval [CI]: 1.44–57.9; p = 0.019).Conclusion: High serum levels of otolin-1 were associated with an increased risk of BPPV recurrence, and further investigation is required to confirm this association and clarify the exact mechanism.
Objective: To evaluate the plasma levels of the otoconial proteins, otoconin-90 and otolin-1, in individuals diagnosed with vestibular neuritis (VN) and determine the feasibility of using these proteins as biomarkers for VN. Methods: In this preliminary study, 30 patients diagnosed with VN and 70 healthy individuals were recruited and followed to confirm whether they had benign paroxysmal positional vertigo (BPPV) during the following time. The recorded data included measurements of height, weight, and history of diabetes mellitus or hypertension. Additionally, levels of plasma otoconin-90, and otolin-1 were measured and compared. Results: The plasma concentrations of otoconin-90 and otolin-1 may not be significantly different between patients with VN and healthy controls, nor among patients with BPPV secondary to VN and patients with VN without BPPV. Conclusions: Plasma otoconin-90 and otolin-1 levels may not serve as biomarkers of acute VN episodes or predict BPPV occurrence secondary to VN.
Objective: Vestibular migraine (VM) is a common cause of episodic vertigo but lacks objective diagnostic biomarkers. The symptomatic overlap of VM with benign paroxysmal positional vertigo (BPPV) and Meniere’s disease (MD) complicates differential diagnosis. Given that elevated serum Otolin-1 and Otoconin-90 (OC90) levels are established biomarkers in BPPV and MD, this study aimed to determine whether these otoconia-derived proteins are also altered in VM. Methods: In this case-control study, 40 patients with definite VM and 143 age- and sex-matched healthy controls were included. Serum samples were collected during the interictal period. Otolin-1 and OC90 levels were quantified using enzyme-linked immunosorbent assays. Results: No significant differences were found in serum levels of Otolin-1 and OC90 between groups. The median (IQR) Otolin-1 level was 215.5 pg/mL (127.5–314.9) in the VM group vs. 200.6 pg/mL (127.7–284.2) in controls (Cliff’s δ = 0.08, p = 0.526). Similarly, the median (IQR) OC90 level was 39.8 ng/mL (29.4–60.8) compared to 32.7 ng/mL (27.9–77.9) in controls (Cliff’s δ = −0.07, p = 0.659). No correlations were observed between protein levels and clinical features. However, within the VM group, serum Otolin-1 levels were highest within 1-week post-attack and declined thereafter, showing a significant negative correlation with time ( r = −0.372, p = 0.018). A similar phase-dependent pattern was observed for OC90 levels across the VM subgroups ( p = 0.017), though without a significant correlation with continuous time. Conclusion: These preliminary findings indicate that serum Otolin-1 and OC90 levels are not altered in patients with VM compared to healthy controls. Exploratory analysis revealed a phase-dependent decrease in Otolin-1 within the VM group post-attack. These results argue against significant structural damage to otoconia in VM and support a central/functional pathophysiology. While not positive diagnostic biomarkers, normal levels of these proteins may provide negative evidence to aid in differentiating VM from BPPV or MD, pending future validation.
Background: Residual dizziness (RD) is a common and debilitating symptom following successful canalith repositioning procedure (CRP) for benign paroxysmal positional vertigo (BPPV). Currently, no effective pharmacological treatment exists for this condition. Our previous work identified low serum 25-hydroxyvitamin D [25(OH)D] as an independent risk factor for RD. This study therefore evaluated whether 8-week supplementation with Caltrate D was associated with improvement in RD. Methods: Female patients with primary BPPV who achieved successful CRP but still complained of RD at day 7 post-CRP and had serum 25(OH)D < 20 ng/mL were enrolled. Patients who took Caltrate D for 8 weeks formed the treatment group, while those who received no vitamin D or calcium supplementation served as the control group. The primary outcome was the improvement rate of the Dizziness Handicap Inventory (DHI) total score at 4 and 8 weeks. Secondary outcomes included duration of RD. Results: Forty-three patients in the treatment group and 48 in the control group completed the study. At 4 and 8 weeks, DHI improvement rates were significantly higher in the treatment group than in the control group (56.2% ± 10.8% vs. 44.4% ± 11.8 and 77.6% ± 6.34% vs. 66.9% ± 9.8%, respectively; both p < 0.001). The median RD duration was also significantly shorter in the treatment group (12 days, IQR 7–18 vs. 19 days, IQR 12–24; p = 0.007) than in the control group. Conclusion: In this retrospective cohort of female BPPV patients with RD and vitamin D deficiency after successful CRP, 8-week Caltrate D supplementation was associated with improvement in DHI score and shortening of RD duration. Prospective studies are warranted to confirm these observations.